Lantern Pharma launched ZetaOmics™, an autonomous computational biology platform designed to support cancer researchers with advanced bioinformatics, biostatistics, and multi-omic analysis capabilities. The platform, part of Lantern’s withZeta.ai AI co-scientist ecosystem, is designed to analyze large-scale cancer datasets, build research cohorts, and generate publication-ready insights while helping researchers identify biological signals more efficiently. Initially available through an early-access program, ZetaOmics aims to expand access to expert-level computational analysis for academic institutions, biotechnology companies, pharmaceutical researchers, and cancer research organizations.
